Back to top

oncology-screening: Archive

Zacks Equity Research

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

BMYNegative Net Change

Zacks Equity Research

GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

GSKPositive Net Change AGENPositive Net Change PBYIPositive Net Change ADMAPositive Net Change